Eye City Vision
Neophore is a pioneering biotechnology company that focuses on discovering small molecule drugs designed to create neoantigens, targeting the dynamics of cancer neoantigen evolution. Their innovative approach aims to develop effective and well-tolerated medicines that will play a crucial role in the next generation of cancer immunotherapies.
With a vision centered on stimulating immunity at the core of cancer, Neophore emphasizes the robust and sustained immune responses observed in certain cancers lacking DNA mismatch repair (MMR) genes. The company continues to strengthen its leadership and resources, recently appointing Michael Shih as Chief Executive Officer and closing an oversubscribed Series B extension round with additional funding from Bristol Myers Squibb.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Partial Data by Foursquare.





